trial · primary record
Sacituzumab tirumotecan
Non-small Cell Lung Cancer (NSCLC)
| Phase | Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 614 |
| Primary completion | 2030-05-27 |
| Primary endpoint | Overall Survival (OS) |
| Registry ID | NCT06170788 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T03:27:45.209Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06170788
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.